NIAID enrolling participants in two COVID-19 monoclonal antibody trialsThe National Institute of Allergy and Infectious Diseases (NIAID) yesterday announced that it is enrolling participants for two phase 3 trials of two different monoclonal antibody treatments for COVID-19.The trials are enrolling healthy adults at risk for infection due to close contact at work or home, and the investigations are part of the COVID-19 Prevention Network recently established by NIAID, the group said in a news release.
Anthony Fauci, MD, NIAID's director, said the network is designed to conduct large-scale trials rapidly and efficiently.One of the trials involves a double monoclonal antibody against SARS-CoV-2 developed by Regeneron and has a goal of